Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 5/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421299 | 0.86 | ALDH1A1 (0.41) | HCAR3ALDH1A1POLB | |
| SCHEMBL25933684 | 0.82 | HCAR3 (0.54) | HCAR3CHRNA7ALDH1A1KDM6BKDM4C | |
| SCHEMBL25933711 | 0.82 | HCAR3 (0.40) | HCAR3HDAC3ALDH1A1L3MBTL1POLB | |
| SCHEMBL24214176 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1POLB | |
| SCHEMBL2122367 | 0.78 | SMN1; SMN2 (0.52) | HCAR3CHRNA7ALDH1A1L3MBTL1POLB | |
| SCHEMBL3826302 | 0.78 | STK17B (0.54) | ALDH1A1POLB | |
| SCHEMBL31132753 | 0.77 | ALDH1A1 (0.47) | HCAR3ALDH1A1POLB | |
| SCHEMBL476528 | 0.77 | ALDH1A1 (0.47) | HCAR3ALDH1A1POLB | |
| SCHEMBL9648858 | 0.76 | ALDH1A1 (0.43) | HCAR3EGLN1ALDH1A1L3MBTL1POLB | |
| SCHEMBL6606946 | 0.76 | ALDH1A1 (0.41) | HCAR3ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HCAR3 2347/4885CHRNA7 1582/4885HDAC3 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.